aTyr Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sanjay Shukla

İcra Kurulu Başkanı

US$1.3m

Toplam tazminat

CEO maaş yüzdesi43.2%
CEO görev süresi7yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi5.9yrs
Yönetim Kurulu ortalama görev süresi15.1yrs

Son yönetim güncellemeleri

Recent updates

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

CEO Tazminat Analizi

Sanjay Shukla'un ücretlendirmesi aTyr Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$1mUS$450k

-US$35m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$45m

Dec 31 2017US$2mUS$403k

-US$48m

Tazminat ve Piyasa: Sanjay 'ın toplam tazminatı ($USD 1.30M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.46M ).

Tazminat ve Kazançlar: Sanjay 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Sanjay Shukla (52 yo)

7yrs

Görev süresi

US$1,300,525

Tazminat

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sanjay Shukla
President7yrsUS$1.30m0.16%
$ 426.0k
Jill Broadfoot
Chief Financial Officer6.3yrsUS$677.84k0.025%
$ 65.0k
Nancy E. Krueger
General Counsel & Corporate Secretary10.1yrsUS$651.28k0.027%
$ 69.5k
Xiang-Lei Yang
Founderno dataVeri yokVeri yok
Jayant Aphale
Vice President of Technical Operationsless than a yearVeri yokVeri yok
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Peter Villiger
Vice President of Corporate Development4.8yrsVeri yokVeri yok
Danielle Campbell
VP of Human Resource2.9yrsVeri yokVeri yok
Leslie Nangle
Vice President of Researchno dataVeri yokVeri yok
Ying Buechler
Executive Director of Biologics Development & Manufacturingno dataVeri yokVeri yok
David King
Scientific Consultant5.9yrsUS$717.31kVeri yok

5.9yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: ATYR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sanjay Shukla
President7yrsUS$1.30m0.16%
$ 426.0k
John Clarke
Independent Director19.2yrsUS$120.84k0.024%
$ 61.8k
Paul Schimmel
Independent Director19.2yrsUS$61.20k1.31%
$ 3.4m
Floyd Bloom
Member of Scientific Advisory Board15.1yrsVeri yokVeri yok
Bruce Beutler
Member of Scientific Advisory Board15.3yrsVeri yokVeri yok
Benjamin Cravatt
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Timothy Coughlin
Independent Chairman of the Board7.6yrsUS$92.20k0.067%
$ 174.7k
Osamu Nureki
Member of Scientific Advisory Board15.2yrsVeri yokVeri yok
Susan Ackerman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Wing Wong
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Nancy Ip
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jane Gross
Independent Director5.3yrsUS$68.88k0.0072%
$ 18.7k

15.1yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ATYR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15.1 yıldır).